Parkinson's disease (PD) is a progressive neurological disorder that primarily affects movement. It is characterized by the degeneration of dopamine-producing neurons in the substantia nigra, a part of the brain that controls movement. This article provides a comprehensive overview of PD, its pathophysiology, clinical manifestations, diagnosis, and treatment options.
The primary pathological feature of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in striatal dopamine levels. This results in an imbalance between the excitatory and inhibitory pathways in the basal ganglia, causing the characteristic motor symptoms of PD. The presence of Lewy bodies, abnormal aggregates of the protein alpha-synuclein, is another hallmark of PD.
PD typically presents with motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms can include autonomic dysfunction, cognitive impairment, mood disorders, and sleep disturbances. The disease progression varies among individuals, with some experiencing rapid progression while others remain stable for several years.
Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and response to dopaminergic medication. Neuroimaging can be used to support the diagnosis but is not definitive. Treatment is symptomatic, with levodopa being the most effective medication. Other treatment options include dopamine agonists, MAO-B inhibitors, and deep brain stimulation for advanced cases.
Understanding the pathophysiology, clinical manifestations, and treatment options for Parkinson's disease is crucial for healthcare professionals. Despite the progress made in managing PD, there is still no cure, and the disease continues to pose significant challenges. Continued research and development in this field are necessary to improve the quality of life for individuals living with PD.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation